Pharmacokinetics and brain distribution studies of 6-hydroxykynurenic acid and its structural modified compounds.

Zhuowei ShenHaihong HuJie PanMingcheng XuFengting OuKaifeng HeKui ZengJianbiao YaoRuwei WangYan LouSu Zeng

Published in: The Journal of pharmacy and pharmacology (2021)

The bioavailability and the brain content of 6-HKA can be improved by the prodrug method. Among three structural modified compounds, isopropyl-esterified 6-HKA was the most promising treatment.

Keyphrases

resting state
white matter
functional connectivity
multiple sclerosis
case control
replacement therapy
blood brain barrier
smoking cessation